

Cover Story
ClinicalRegulatory NewsTrials & Tribulations
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
Cancer Policy
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- Charles Rudin named cancer center director at MSK
- Pam Bondi diagnosed with thyroid cancer
- As FDA’s wheels almost entirely come off, NCI remains sturdy—a cancer moonshot may even be on the horizon
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- UK Markey’s Denise Fabian: Theranostics lets us pair a diagnostic with a radioactive therapeutic that target the same molecule

















